Treatment of patients with chronic hepatitis C who failed the triple therapy with first generation of protease inhibitors is not still defined. The combined use of sofosbuvir (SOF) and daclatasvir (DCV) seems to be promising due to higher genetic barrier, good tolerance and effectiveness.
Treatment with daclatasvir and sofosbuvir for 24 weeks without ribavirin in cirrhotic patients who failed first-generation protease inhibitors
BOGLIONE, Lucio
First
;CARDELLINO, Chiara Simona;DE NICOLO', AMEDEO;CUSATO, JESSICA;CARCIERI, CHIARA;DI PERRI, Giovanni;D'AVOLIO, ANTONIOLast
2017-01-01
Abstract
Treatment of patients with chronic hepatitis C who failed the triple therapy with first generation of protease inhibitors is not still defined. The combined use of sofosbuvir (SOF) and daclatasvir (DCV) seems to be promising due to higher genetic barrier, good tolerance and effectiveness.
File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
10.1007%2Fs15010-016-0962-3.pdf
Accesso riservato
Tipo di file:
PDF EDITORIALE
Dimensione
412.05 kB
Formato
Adobe PDF
|
412.05 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
